Curated News
By: NewsRamp Editorial Staff
June 12, 2026

Tonix Pharmaceuticals to Present at BTIG Infectious Disease Day 2026

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Tonix Pharmaceuticals management will hold one-on-one meetings at BTIG Infectious Disease Day 2026, offering direct access for investors.
  • Tonix is a commercial-stage biotech with approved fibromyalgia drug TONMYA and a pipeline of CNS and immunology candidates.
  • Tonix addresses high unmet medical needs with treatments for fibromyalgia, depression, rare diseases, Lyme disease, and transplant rejection.
  • TONMYA is the first new fibromyalgia treatment in over 15 years, offering hope to millions of patients.

Impact - Why it Matters

This news matters because Tonix Pharmaceuticals is at the forefront of developing treatments for conditions with high unmet medical needs, such as fibromyalgia, Lyme disease, and transplant rejection. The company's participation in a key investor event signals potential advancements that could directly affect patients suffering from these conditions. For investors, Tonix's pipeline diversity and commercial success offer a unique opportunity in the biotech sector. The broader biotech community benefits from Tonix's integrated approach, which could set a precedent for combining CNS and immunology research. Moreover, the use of InvestorWire for dissemination highlights the critical role of targeted communication in ensuring that impactful news reaches the right audience, influencing both public health and market dynamics.

Summary

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial-stage biotechnology company, announced that its management team, led by President and CEO Seth Lederman, M.D., will participate in one-on-one meetings at BTIG’s Infectious Disease Day 2026, a virtual event scheduled for June 16, 2026. This participation underscores Tonix's commitment to advancing its pipeline in infectious diseases and other high-need areas. The company, known for its focus on central nervous system (CNS) and immunology treatments, recently gained FDA approval for TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. Tonix's CNS commercial infrastructure also supports its acute migraine products, Zembrace® SymTouch® and Tosymra®. Beyond CNS, Tonix is maximizing the science behind TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, while its pipeline includes TNX-2900 for Prader-Willi syndrome, a rare disease. In immunology, the company is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention. These developments highlight Tonix's diversified approach to addressing unmet medical needs. For more details, the full press release can be accessed via the provided link. Investors can find the latest news and updates relating to TNXP in the company’s newsroom at https://ibn.fm/TNXP.

Tonix's participation in BTIG's Infectious Disease Day reflects its strategic focus on infectious disease research, particularly through its immunology programs like TNX-4800 for Lyme disease. The company's leadership in this space is bolstered by its integrated approach, combining CNS and immunology expertise. The virtual event format allows for efficient engagement with investors, highlighting Tonix's progress and future directions. As a commercial-stage company, Tonix balances marketed products with a robust pipeline, positioning itself for growth in multiple therapeutic areas.

The news also features InvestorWire (IW), a specialized communications platform that syndicated this press release. InvestorWire, part of the Dynamic Brand Portfolio @ IBN, offers services including press release distribution, editorial syndication to over 5,000 outlets, and social media distribution. IW's enhanced press release capabilities aim to maximize impact for companies like Tonix, ensuring broad reach among investors and the public. This partnership underscores the importance of effective communication in the biotech sector, where timely news can influence investment decisions.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals to Present at BTIG Infectious Disease Day 2026

blockchain registration record for this content.